# MCAS drivers and comorbidities

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Guide
Updated: 2026-10-16
Canonical: https://heretic.bio/articles/mcas-drivers-and-comorbidities.html

> Mast cells respond to a wide range of signals — IgE, complement, neuropeptides, CRH, estrogen, TLR ligands, certain foods, certain metals, certain drugs, and physical triggers — and "total load" (multiple small triggers stacking) is a clinically useful heuristic. But each individual trigger needs its own evidence audit, and most claims about a "trigger" are at best mechanistically plausible and at worst marketing-grade speculation.

This file scores the specific trigger/comorbidity hypotheses @BioavailableNd promotes. Ratings use the Source Evaluation Framework (5 = RCT/SR; 1 = anecdote); translation levels T0–T5; causal confidence low/moderate/high per Bradford-Hill add-on.

## Triggers Andra names

#### Stress, CRH, and the mast cell–gut axis

  * **Andra's claim:** chronic stress is a primary driver; mast cells respond to CRH.
  * **What the literature says:** psychological stress and exogenous CRH increase intestinal permeability in humans in a mast-cell-dependent mechanism (PMID [24153250](https://pubmed.ncbi.nlm.nih.gov/24153250/), n=11 healthy controls, CRH 1 µg/kg IV; increased permeability blocked by mast-cell stabilizer).[110] CRH receptors on mast cells are well-documented.
  * **Evidence rating:** 4\. **Translation:** T4. **Causal confidence:** moderate. **Verdict:** **Supported mechanism.**



#### Hormones — estrogen

  * **Andra's claim:** estrogen activates mast cells; endometriosis, PCOS, and perimenstrual flares reflect this.
  * **What the literature says:** E2 directly triggers mast cell degranulation in RBL2H3 cells and in ovarian endometriomas (PMID [29074615](https://pubmed.ncbi.nlm.nih.gov/29074615/)); mast cell numbers and activation state are elevated in endometriosis lesions and correlate with dysmenorrhea severity.[20][19] Endometriotic cells recruit mast cells via SCF/TGF-β/MCP-1 release in response to E2.[20] A 2016 paper notes that genitourinary mast cells express estrogen, gonadotropin, and CRH receptors and respond to estrogen.[68]
  * **Evidence rating:** 4 (mechanism) / 3 (clinical association). **Translation:** T3–T4. **Causal confidence:** moderate for reproductive-tissue mast cell activation; weaker for general "E2 → MCAS."
  * **Verdict:** **Supported for endometriosis/ovarian end-organ; partially supported for systemic E2 → MCAS.**



#### Mold and CIRS

  * **Andra's claim:** mold exposure drives mast cell activation; CIRS is essentially an MCAS variant.
  * **What the literature says:** the CIRS literature (Shoemaker et al.) shows inflammatory markers (TGF-β1, MMP9, C4a, VEGF) elevated in patients exposed to water-damaged buildings.[28][24][25] Mycotoxin exposure causes immune dysregulation (PMID [29752039](https://pubmed.ncbi.nlm.nih.gov/29752039/), PMID [29880330](https://pubmed.ncbi.nlm.nih.gov/29880330/)). Mycotoxins from _Fusarium oxysporum_ cause skin inflammation and mast-cell activation (PMID [19570074](https://pubmed.ncbi.nlm.nih.gov/19570074/)).[113]
  * **However:** the _Aspergillus_ metabolite **gliotoxin** directly _suppresses_ mast cell degranulation via calcium and superoxide pathways (PMID [16213796](https://pubmed.ncbi.nlm.nih.gov/16213796/)) — the opposite of "mold drives mast cells."[27] The clinical CIRS literature is dominated by a single research group with limited independent replication.[24] A 2024 systematic review of CIRS treatment found only Shoemaker-protocol studies.[24]
  * **Evidence rating:** 2\. **Translation:** T2. **Causal confidence:** low.
  * **Verdict:** **Plausible symptom overlap; mechanism mixed; evidence is not robust enough to claim mold→MCAS causally.**



#### Nickel and metals

  * **Andra's claim:** nickel acts as an estrogen and activates mast cells; nickel drives SNAS, endometriosis, PCOS, eczema, GERD.
  * **What the literature says:**
  * Nickel is a **metalloestrogen** — it activates estrogen receptor α in vitro and in vivo (PMID [16489580](https://pubmed.ncbi.nlm.nih.gov/16489580/), Martin et al.).[47]
  * **Nickel allergy is associated with endometriosis** in two population-based studies — an 11-year nested case-control (PMID [26439741](https://pubmed.ncbi.nlm.nih.gov/26439741/)) and a 3-year cross-sectional study showing significantly higher nickel allergy prevalence in endometriosis patients (PMID [25976177](https://pubmed.ncbi.nlm.nih.gov/25976177/)).[49][50]
  * **Systemic Nickel Allergy Syndrome (SNAS)** is a real entity: cutaneous + GI + extra-cutaneous symptoms in nickel-sensitized individuals after dietary exposure; treated by low-nickel diet, oral hyposensitization, and probiotics.[10][11][81][80][79]
  * **Oral hyposensitization** to nickel reduces symptoms and shifts TH1/TH2 cytokine balance (PMID [20378005](https://pubmed.ncbi.nlm.nih.gov/20378005/)).[81]
  * **Probiotic supplementation** in SNAS reduces lactobacilli population shift and improves symptoms (PMID [25363062](https://pubmed.ncbi.nlm.nih.gov/25363062/)).[80]
  * The role of nickel as a direct _mast cell activator_ (as opposed to a Type IV contact allergen) is less well-documented in non-sensitized individuals; in SNAS patients the clinical picture is mast-cell-like.
  * **Evidence rating:** 3 (estrogen-like); 3 (SNAS); 2 (mast cell activator). **Translation:** T3. **Causal confidence:** moderate for endometriosis association and SNAS; lower for nickel as a primary MCAS driver.
  * **Verdict:** **The metalloestrogen and endometriosis links are real; the claim that nickel "activates mast cells" in the way Andra implies is supported only in sensitized individuals.**



#### Infections (post-COVID, Lyme, etc.)

  * **Andra's claim:** unresolved infections drive MCAS; long COVID is largely MCAS.
  * **What the literature says:**
  * Mast-cell-related symptoms are highly prevalent in long COVID (PMID [34563706](https://pubmed.ncbi.nlm.nih.gov/34563706/), Afrin et al.).[38]
  * Viral infections and vaccinations can trigger chronic urticaria (PMID [37515272](https://pubmed.ncbi.nlm.nih.gov/37515272/)).[122]
  * Famotidine (H2 blocker) reduced cytokine storm and improved POTS-like hyperadrenergic POTS in a single case report (PMID [38526146](https://pubmed.ncbi.nlm.nih.gov/38526146/)).[67]
  * COVID vaccines can transiently worsen mast cell symptoms in susceptible patients (PMID [38176772](https://pubmed.ncbi.nlm.nih.gov/38176772/), 34791757).[64][125]
  * However, the same 2024 single-center study (PMID [38056692](https://pubmed.ncbi.nlm.nih.gov/38056692/)) that tested suspected MCAS patients found that very few met consensus-1 criteria, suggesting post-COVID symptoms that _feel_ like MCAS often have other explanations (autonomic dysfunction, EBV reactivation, hypermobility spectrum disorder).[128]
  * **Evidence rating:** 3\. **Translation:** T3. **Causal confidence:** moderate for symptom overlap; lower for full MCAS criteria.
  * **Verdict:** **Real symptom overlap with MCAS; under strict criteria, fewer than expected meet full MCAS diagnosis.**



#### Foods (other than dairy)

  * **Andra's claim:** high-histamine foods, fermented foods, wine trigger MCAS.
  * **What the literature says:** a 2025 review of histamine content in Brazilian foods shows the expected high-histamine categories (aged cheeses, fermented vegetables, cured meats, wine, certain fish).[70] Wine-induced headache involves histamine among other amines (PMID [36514756](https://pubmed.ncbi.nlm.nih.gov/36514756/), 27699780, 15806385).[136][137][138] Low-histamine diets show modest efficacy in atopic dermatitis (PMID [40431369](https://pubmed.ncbi.nlm.nih.gov/40431369/)) and chronic urticaria (PMID [34826140](https://pubmed.ncbi.nlm.nih.gov/34826140/), 39236849, 40880715).[39][120][119][118]
  * **Evidence rating:** 3\. **Translation:** T3. **Causal confidence:** moderate for HIT subgroup; low for MCAS subgroup.
  * **Verdict:** **Supported for HIT; not specifically demonstrated for MCAS.**



## Comorbidities Andra lists

Condition | Evidence link to MCAS | Citation  
---|---|---  
Endometriosis | Moderate; mast cells in lesions, E2-driven activation, nickel-allergy association | [19][20][49][50]  
PCOS | None direct; some via obesity/insulin resistance/DAO deficiency; one Andra-specific claim | [unverified]  
Eczema / atopic dermatitis | Moderate; low-histamine diet helps subgroup, [EAS] dietary amine elimination shows effect | [39][143]  
GERD | Weak; histamine can trigger gastric acid; some overlap | [73]  
Rosacea | Strong for mast cell involvement; H. pylori link _disproven_ in MR studies | [60][61][140][142]  
IBS / SIBO | Moderate; mast cell density increased in IBS mucosa; stress-mast cell-permeability axis | [109][110][139]  
Hyperadrenergic POTS / Dysautonomia | Strong clustering; "firmly established" 2024 | [147][71][126]  
Hypermobile EDS | Strong clustering; GI manifestations reviewed by AGA | [147][71][145]  
Long COVID | Moderate symptom overlap; small minority meet consensus-1 MCAS | [38][21][128]  
Fibromyalgia | Positive small RCT for DAO supplementation; modest mechanistic support | [82]  
Chronic urticaria | Direct relationship; treated with omalizumab | [69][122]  
ADHD | Mechanistic animal only (H2 → dopamine); no human MCAS trial | [55][56][57]  
  
## Speculative links (low evidence)

Claim | Evidence rating | Translation | Verdict  
---|---|---|---  
ADHD as "a histamine problem" | 1 | T1 | Mechanistic animal data (H2 receptor on parvalbumin neurons in substantia nigra; H2 modulation of striatal dopamine); no human MCAS-ADHD trial. Hypothesis, not treatment.  
nnEMF drives MCAS | 1 | T1 | Animal histology only (atrazine + 50 Hz EMF combined exposure increased cutaneous mast cell degranulation in juvenile rats; ELF-EMF increased thyroid mast cell density); no human MCAS trial.  
Limbic "danger mode" / DNRS as MCAS treatment | 1 | T0–T1 | No primary MCAS trial of Annie Hopper's DNRS or any limbic-retraining program in MCAS specifically. Theoretical.  
Organotherapy for MCAS | 1 | T0 | Historical practice; no modern trial.  
Cell salts / biochemic tissue salts for MCAS | 1 | T0 | No peer-reviewed trial in MCAS or any related condition.  
MCAS causes weight gain or lipedema | 1 | T0 | Andra has written about this on Substack; no primary literature supports a direct lipedema-MCAS causal mechanism.  
  
## Method note

Each claim is rated against the strongest available primary literature. The "androgenic" / "estrogenic" / "allergic" / "neurological" / "autoimmune" / "metabolic" lines are kept separate because the evidence base differs across them.

## Notes

  * The single most useful clinical test of "does this patient's MCAS respond to addressing the trigger?" is the **provocation-and-dechallenge** design: e.g., nickel avoidance + low-nickel diet in suspected SNAS + MCAS, then re-introduction.
  * For the "total load" model, the practical question is which triggers actually matter _for this patient_ — the patient can only work the list that applies to them, not the full population-level list.
  * The fact that mast cells express receptors for estrogen, CRH, neuropeptide Y, substance P, IgE, complement, and TLR ligands is _why_ they sit at the center of so many chronic-disease hypotheses. It is also _why_ so many of those hypotheses are unfalsifiable without objective mediator measurement.

## Sources

1. PubMed 24153250 (PubMed 24153250)
2. PubMed 29074615 (PubMed 29074615)
3. PubMed 29752039 (PubMed 29752039)
4. PubMed 29880330 (PubMed 29880330)
5. PubMed 19570074 (PubMed 19570074)
6. PubMed 16213796 (PubMed 16213796)
7. PubMed 16489580 (PubMed 16489580)
8. PubMed 26439741 (PubMed 26439741)
9. PubMed 25976177 (PubMed 25976177)
10. PubMed 20378005 (PubMed 20378005)
11. PubMed 25363062 (PubMed 25363062)
12. PubMed 34563706 (PubMed 34563706)
13. PubMed 37515272 (PubMed 37515272)
14. PubMed 38526146 (PubMed 38526146)
15. PubMed 38176772 (PubMed 38176772)
16. PubMed 38056692 (PubMed 38056692)
17. PubMed 36514756 (PubMed 36514756)
18. PubMed 40431369 (PubMed 40431369)
19. PubMed 34826140 (PubMed 34826140)
20. PubMed 41994619 (PubMed 41994619)
21. PubMed 21409856 (PubMed 21409856)
22. PubMed 31424502 (PubMed 31424502)
23. PubMed 35785029 (PubMed 35785029)
24. PubMed 39649915 (PubMed 39649915)
25. PubMed 25889530 (PubMed 25889530)
26. PubMed 36069791 (PubMed 36069791)
27. PubMed 42763339 (PubMed 42763339)
28. PubMed 40355265 (PubMed 40355265)
29. PubMed 39788124 (PubMed 39788124)
30. PubMed 2221490 (PubMed 2221490)
31. PubMed 2731601 (PubMed 2731601)
32. PubMed 35736349 (PubMed 35736349)
33. PubMed 42807181 (PubMed 42807181)
34. PubMed 41256231 (PubMed 41256231)
35. PubMed 40387691 (PubMed 40387691)
36. PubMed 42039449 (PubMed 42039449)
37. PubMed 36143107 (PubMed 36143107)
38. PubMed 37892588 (PubMed 37892588)
39. PubMed 32649443 (PubMed 32649443)
40. PubMed 40880715 (PubMed 40880715)
41. PubMed 39236849 (PubMed 39236849)
42. PubMed 34791757 (PubMed 34791757)
43. PubMed 40809669 (PubMed 40809669)
44. PubMed 27699780 (PubMed 27699780)
45. PubMed 15806385 (PubMed 15806385)
46. PubMed 42346839 (PubMed 42346839)
47. PubMed 42515667 (PubMed 42515667)
48. PubMed 40963887 (PubMed 40963887)
49. PubMed 34564936 (PubMed 34564936)
50. PubMed 42788166 (PubMed 42788166)
51. PubMed 40352770 (PubMed 40352770)